Does Your Business Have the Tools to Compete in the World's Largest Diagnostics Markets?

• Frost & Sullivan participates in IVD Business Strategy Conference evaluating useful approaches to excel in a cost-constrained industry

MOUNTAIN VIEW, Calif., Oct. 30, 2013 /PRNewswire/ -- The inclusive and increasingly competitive in vitro diagnostics (IVD) landscape is evolving in unison with healthcare reform. Therefore, it is vital for all market participants to understand the transformation and manage amidst the changes.  Those even remotely invested in the market require crucial insight on business strategy and regulatory and technological advancements essential for success, in addition to current and future growth trends and market opportunities that will keep them a key player.

"Global IVD companies have been forced to adjust to a lower healthcare spending baseline for what is currently the world's largest IVD market, the United States," said Frost & Sullivan Life Sciences Senior Industry Analyst Winny Tan. "We used to describe the diagnostics market as highly cost-sensitive; now it is the entire healthcare industry that is cost-constrained. Competing in this business environment means growth strategies need to deliver the greatest value with low upfront investments. Potential strategies that fit a cost-constrained industry include identifying underpenetrated markets, leveraging external innovation partners and taking advantage of existing data."

To evaluate these strategies, Tan participates in IVD Business Strategy Conference (http://www.ivdtconference.com/), taking place Nov. 6-8, 2013, in San Diego, Calif.  Her presentation, "Evaluating Diagnostic Industry Growth Trends and Market Opportunities in Global Markets," is on day one of the event and will provide a competitive overview through an analysis of the global IVD market; an evaluation of market revenue opportunities, segment sizes and growth rates; and an assessment of emerging IVD markets.

IVD Business Strategy Conference 2013 provides a full scope view of the business strategy, regulatory and technology advancements essential to generating success in the IVD marketplace.  The event will feature real world case studies by providers as well as a half-day supplemental workshop on reimbursement strategies facilitated by Emerson Consulting.

This all-inclusive two-day conference program covers a range of topics to develop and successfully commercialize in vitro diagnostics, including what's to come for the IVD business landscape and identifying domestic and global growth trends and opportunities; pinpointing regulatory submission requirements for the U.S., Europe, and emerging markets and determining the best documentation approach for speed to market; applying the latest technology in sequencing, molecular diagnostics, wireless, and point of care devices to enhance your IVD product portfolio; and tackling challenges in regulatory approval, pricing, co-development, and relationship management when developing a companion diagnostic.

The conference is suited for IVD manufacturers looking for key regulatory, business and technical updates, as well as pharmaceutical companies looking to enter the personalized medicine arena. All top-level professionals from the following functions will benefit: companion diagnostics, personalized medicine, research and development, business development, manufacturing, regulatory affairs, innovation, pipeline/portfolio, and planning and project management.

The partnership with IVD Business Strategy Conference is part of Frost & Sullivan's Life Sciences Growth Partnership Service program.  Connect with us on social media, including Twitter, Facebook, SlideShare, and LinkedIn, for the latest news and updates.